Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: A preliminary report

Journal of Clinical Oncology

Volumn 27, Issue 11, 2009, Pages 1767-1773

  Nishizawa, Sadahiko ^a   Kojima, Shinsuke ^a   Teramukai, Satoshi ^a   Inubushi, Masayuki ^a   Kodama, Hironobu ^a   Maeda, Yoshiki ^a   Okada, Hiroyuki ^a   Zhou, Bin ^a   Nagai, Yoji ^a   Fukushima, Masanori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM CANCER; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; THYMUS CANCER; THYROID CANCER; WHOLE BODY SCINTISCANNING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; OCCULT BLOOD; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 64649093420     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.2238     Document Type: Article

References (27)

1. National Cancer Institute: Cancer screening overview (PDQ®). http://www.cancer.gov/cancertopics/ pdq/screening/overview/healthprofessional
2. Agress H Jr, Cooper BZ: Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: Histopathologic comparison. Radiology 230:417-422, 2004
3. Ishimori T, Patel PV, Wahl RL: Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 46:752-757, 2005
4. 18F-fluorodeoxyglucose positron-emission tomography. Lancet 350:1819, 1997
5. Yasuda S, Ide M, Fujii H, et al: Application of positron emission tomography imaging to cancer screening. Br J Cancer 83:1607-1611, 2000
6. Shen YY, Su CT, Chen GJ, et al: The value of 18F-fluorodeoxyglucose positron emission tom ography with the additional help of tumour markers in cancer screening. Neoplasma 50:217-221, 2003
7. Chen YK, Ding HJ, Su CT, et al: Application of PET and PET/CT imaging for cancer screening. Anticancer Res 24:4103-4108, 2004
8. Kojima S, Zhou B, Teramukai S, et al: Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study. Eur J Cancer 43:1842-1848, 2007
9. Minamimoto R, Senda M, Uno K, et al: Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 21:481-498, 2007
10. Schoder H, Gönen M: Screening for cancer with PET and PET/CT: Potential and limitations. J Nucl Med 48:4S-18S, 2007 (suppl 1)
11. Ide M, Suzuki Y: Is whole-body FDG-PET valuable for health screening? For. Eur J Nucl Med Mol Imaging 32:339-341, 2005
12. Weckesser M, Schober O: Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging 32:342-343, 2005
13. Yasuda S, Ide M: PET and cancer screening. Ann Nucl Med 19:167-177, 2005
14. Watanabe M, Shimizu K, Omura T, et al: A high-throughput whole-body PET scanner using flat panel PS-PMTs. IEEE Trans Nucl Sci 51:796-800, 2004
15. Tanaka E, Kudo H: Subset-dependent relaxation in block-iterative algorithms for image reconstruction in emission tomography. Phys Med Biol 48:1405-1422, 2003
16. National Cancer Center, Japan: Cancer statistics in Japan 2007 [in Japanese]. http://ganjoho.ncc.go.jp/public/statistics/backnumber/2007-jp.html
17. Nanda K, McCrory DC, Myers ER, et al: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med 132:810-819, 2000
18. Moss SM: Breast cancer, in Kramer BS, Gohagan JK, Prorok PC (eds): Cancer Screening. New York, NY, Marcel Dekker, 1999, pp 219-265
19. Cuzick J: Colorectal cancer, in Kramer BS, Gohagan JK, Prorok PC, (eds): Cancer Screening. New York, NY, Marcel Dekker, 1999, pp 143-193
20. Pastorino U, Bellomi M, Landoni C, et al: Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 362:593-597, 2003
21. Henschke CI, Yankelevitz DF, Naidich DP, et al: CT screening for lung cancer: Suspiciousness of nodules according to size on baseline scans. Radiology 231:164-168, 2004
22. Shreve PD, Anzai Y, Wahl RL: Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. RadioGraphics 19:61-77, 1999
23. Doebert N, Namscho N, Menzel C, et al: Limitation of dual time point FDG-PET imaging in the evaluation of focal abdominal regions. Nuklearmedi-zin 43:143-149, 2004
24. 18F-FDG PET. J Nucl Med 46:1819-1824, 2005
25. 18F-FDG uptake in the ovary and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 32:549-556, 2005
26. Nishizawa S, Kido A, Inubushi M, et al: Incidence and characteristics of uterine leiomyomas with FDG uptake. Ann Nucl Med 22:803-810, 2008
27. Bar-Shalom R, Yefremov N, Guralnik L, et al: Clinical performance of PET/CT in evaluation ofcancer: Additional value for diagnostic imaging and patient management. J Nucl Med 44:1200-1209, 2003